Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates

Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs. Parabilis is set to receive $125m, including a $50m upfront payment and a $75m investment, subject to agreed conditions. The partnership will investigate Helicons as standalone therapies and as components of AHCs for potential new therapies. Credit: Gorodenkoff / Shutterstock.com. Regeneron Pharmaceuticals has signed a $2.32bn research collaboration with Parabilis Medicines to develop therapeutic candidates leveraging the latter’s Helicon peptide platform, with an emphasis on antibody-Helicon conjugates (AHCs). Helicons are stabilised, cell-penetrant alpha-helical peptides engineered to interact with intracellular protein targets,…

Source: Pharmaceutical Technology